Company Filing History:
Years Active: 2025
Title: Brian Mcneil Cochran: Innovator in KRAS G12C Inhibitor Compounds
Introduction
Brian Mcneil Cochran is a notable inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds targeting KRAS G12C mutations. With a total of 2 patents to his name, Cochran's work is paving the way for advancements in cancer treatment.
Latest Patents
Cochran's latest patents include the synthesis of key intermediates for KRAS G12C inhibitor compounds. The present invention relates to an improved, efficient, and scalable process to prepare intermediate compounds, such as compound 5M. This compound has a structure that is useful for the synthesis of compounds that specifically target KRAS G12C mutations, which are known to play a critical role in various cancers.
Career Highlights
Cochran is currently employed at Amgen Inc., a leading biotechnology company. His work at Amgen focuses on innovative solutions in drug development, particularly in oncology. His contributions have been instrumental in advancing therapeutic options for patients with specific genetic mutations.
Collaborations
Cochran has collaborated with several talented individuals in his field, including Andrew Thomas Parsons and William Powazinik. These collaborations have fostered a productive environment for innovation and research.
Conclusion
Brian Mcneil Cochran is a distinguished inventor whose work in the synthesis of KRAS G12C inhibitor compounds is making a significant impact in cancer research. His patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.